Rozanolixizumab (Rystiggo) – PA Criteria

HCPC: J9333

Rozanolixizumab (Rystiggo) is a neonatal Fc receptor antagonist indicated for the treatment for generalized myasthenia gravis (gMG) in both anti-acetylcholine receptor (AChR) antibody positive and anti-muscle-specific tyrosine kinase (MuSK) antibody positive adults. It is covered by South Dakota Medicaid following prior authorization when the patient meets the following criteria:

- **Initial Therapy (must meet all):**
  - Therapy is requested by or in consultation with a neurologist
  - Individual is ≥18 years of age
  - Individual has a documented diagnosis of gMG with labs confirming the presence of **one** of the following:
    - Anti-AChR antibodies
    - Anti-MuSK antibodies
  - Individual has a Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of Class II-IV disease
  - Documentation is submitted indicating the patient's Baseline Quantitative Myasthenia Gravis (QMG) score
  - MG-Activities of Daily Living (MG-ADL) total score of ≥3
  - Individual meets previous therapy trials as specified per indication
    - AChR+ Disease
      - Documentation is provided indicating inadequate response or contraindication to pyridostigmine and corticosteroids
      - Individual has failed treatment with at least 2 immunosuppressive therapies (ex., azathioprine, cyclosporine, mycophenolate, cyclophosphamide, methotrexate, tacrolimus etc.) over the course of the last 12 months OR has failed at least 1 immunosuppressive therapy and required chronic plasmapheresis, plasma exchange (PE) or intravenous immunoglobulin (IVIG)
      - Individual has failed treatment with efgartigimod alfa (Vyvgart) and ravulizumab (Ultomiris)
    - MuSK+ Disease
      - Documentation is provided indicating inadequate response or contraindication to corticosteroids
      - Documentation is provided indicating failure, contraindication or inadequate response to rituximab
  - Individual is not using in combination with other myasthenia gravis therapies (Ex. Vyvgart, Ultomiris, Soliris)
  - Approval duration: 6 months
- **Continuation of Therapy (must meet all):**
  - Individual continues to meet initial criteria
  - Individual has had a positive response to therapy as indicated by a reduction in the Myasthenia Gravis-Specific Activities of Daily Living scale (MG-ADL) from pretreatment baseline
  - Improvement in the Quantitative Myasthenia Gravis (QMG) total score
  - Approval duration: 1 year